SynCardia Prepares For IPO
Thinkstock Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering is valued up to $40 million.…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering is valued up to $40 million. The company intends to file on the NASDAQ Global Market under the symbol TAHT.
The sole underwriter for the offering is Roth Capital Partners.
This is a medical technology company focused on developing, manufacturing and commercializing the SynCardia temporary Total Artificial Heart (TAH-t), an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
The SynCardia TAH-t is the only total artificial heart that is commercially available in the U.S., Europe and Canada for use as a bridge to heart transplantation. As a total artificial heart, the SynCardia TAH-t replaces the functionality of both the left and right ventricles of the heart as well as all four heart valves. In combination with an external driver that delivers precisely calibrated pulses of air, the SynCardia TAH-t provides blood flow of up to 9.5 liters per minute through each ventricle, lowering central venous pressure and promoting the recovery of other vital organs.
The company requires each medical center to be trained and certified in the implantation of the SynCardia TAH-t and appropriate patient aftercare before it will sell its device to the center. SynCardia refer to centers that have successfully completed these certification programs as “SynCardia Certified Centers.” At the end of June, 2015, over 1,470 SynCardia TAH-ts (including predecessors) had been implanted across 120 medical centers globally.
In the filing SynCardia detailed its use of the proceeds to pay down its indebtedness as well as funding for clinical trials, building sales and marketing capabilities, and for working capital and general corporate purposes. Separately the company said that it expects that the net proceeds from this offering and the existing cash and cash equivalents, together with potential cash receipts from the sale of its products, will be sufficient to fund operations through at least the next 12 months.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
